Abstract
Hematopoietic SCT (HSCT) is a well-recognized therapeutic procedure to prolong life and cure patients with life-threatening hematological malignancies; however, the risk of developing secondary carcinoma may increase in long-term survivors. The objective of this study was to determine the incidence and risk factors for secondary squamous carcinoma after HSCT. Between 1984 and 2004, 170 allogeneic HSCT recipients aged >15 years, who had survived for >5 years were enrolled. Demographic data and the characteristics of secondary carcinoma were collected and analyzed for the determination of the incidence and risk of developing secondary carcinoma. Eight patients developed secondary carcinoma, including five oral squamous cell carcinomas, one esophageal, one gastric and one ovarian carcinoma, but no cutaneous carcinomas were detected at a median follow-up of 14.1 years (range, 5.1–23.3 years) after HSCT. The accrual 10-year cumulative incidence of secondary carcinoma was 2.89%. In univariate and multivariate analyses, chronic GVHD and age >40 years at the time of HSCT were both significant risk factors independently associated with the development of secondary carcinoma. Thus, the occurrence of secondary carcinoma is one of the late complications in patients undergoing HSCT. Oral squamous cell carcinoma was more common in our patients after HSCT, indicating the need for lifelong surveillance of the oral cavity. Moreover, because of the relatively long latency in developing secondary carcinoma, extended follow-up is required for a thorough understanding of the incidence and characteristics of secondary carcinoma after HSCT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Marras TK, Szalai JP, Chan CK, Lipton JH, Messner HA, Laupacis A . Pulmonary function abnormalities after allogeneic marrow transplantation: a systematic review and assessment of an existing predictive instrument. Bone Marrow Transplant 2002; 30: 599–607.
Hasegawa W, Pond GR, Rifkind JT, Messner HA, Lau A, Daly AS et al. Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation. Bone Marrow Transplant 2005; 35: 51–55.
Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL . New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352–1358.
Bhatia S, Louie AD, Bhatia R, O’Donnell MR, Fung H, Kashyap A et al. Solid cancer after bone marrow transplantation. J Clin Oncol 2001; 19: 464–471.
Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socíe G, Travis LB et al. Solid cancer after bone marrow transplantation. N Engl J Med 1997; 336: 897–904.
Shimada K, Yokozawa T, Atsuta Y, Kohno A, Maruyama F, Yano K et al. Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis. Bone Marrow Transplant 2005; 36: 115–121.
Ahmad I, Cau NV, Kwan J, Maaroufi Y, Meuleman N, Aoun M et al. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation. Transplantation 2009; 87: 1240–1245.
Landgren O, Gilbert ES, Rizzo JD, Socíe G, Banks PM, Sobocinski KA et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 4992–5001.
Curtis RE, Metayer C, Rizzo JD, Socíe G, Sobocinski KA, Flowers ME et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 2005; 105: 3802–3811.
Rugarli C, Smeraldi RS, Villa MG, Pello F . HL-A antigens in serum from bone marrow harvested for diagnostic purposes. Biomedicine 1976; 25: 100–104.
Little AM, Marsh SG, Madrigal JA . Current methodologies of human leukocyte antigen typing utilized for bone marrow donor selection. Curr Opin Hematol 1998; 5: 419–428.
Rizzo JD, Curtis RE, Socié G, Sobocinski KA, Gilbert E, Landgren O et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1175–1183.
Socié G, Curtis RE, Deeg HJ, Sobocinski KA, Filipovich AH, Travis LB et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000; 18: 348–357.
Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC . Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med 1995; 24: 450–453.
D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944–1956.
Fakhry C, Gillison ML . Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006; 24: 2606–2611.
Savani BN, Goodman S, Barrett AJ . Can routine post-transplant HPV vaccination prevent commonly occurring epithelial cancers after allogeneic stem cell transplantation? Clin Cancer Res 2009; 15: 2219–2221.
Chen MH, Hsiao LT, Chiou TJ, Liu JH, Gau JP, Teng HW et al. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma. Ann Hematol 2008; 87: 475–480.
Janin A, Murata H, Leboeuf C, Cayuela JM, Gluckman E, Legrès L et al. Donor-derived oral squamous cell carcinoma after allogeneic bone marrow transplantation. Blood 2009; 113: 1834–1840.
Acknowledgements
This work was partially supported by the Taiwan Clinical Oncology Research Foundation.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Chen, M., Chang, P., Li, W. et al. High incidence of oral squamous cell carcinoma independent of HPV infection after allogeneic hematopoietic SCT in Taiwan. Bone Marrow Transplant 46, 567–572 (2011). https://doi.org/10.1038/bmt.2010.163
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2010.163
Keywords
This article is cited by
-
Oral microbial changes and oral disease management before and after the treatment of hematological malignancies: a narrative review
Clinical Oral Investigations (2023)
-
Secondary oral cancer following hematopoietic cell transplantation
Bone Marrow Transplantation (2021)
-
Clinicopathologic characteristics of secondary squamous cell carcinoma of head and neck in survivors of allogeneic hematopoietic stem cell transplantation for hematologic malignancies
Bone Marrow Transplantation (2019)
-
Aggressive skin cancers in patients who experienced chronic GvHD after allogeneic bone marrow transplantation
Bone Marrow Transplantation (2017)
-
Use of azathioprine for graft-vs-host disease is the major risk for development of secondary malignancies after haematopoietic stem cell transplantation: a nationwide population-based study
British Journal of Cancer (2015)